Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06269120 | RECRUITING | Type 2 Diabetes

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
Sponsor:

Novo Nordisk A/S

Brief Summary:

Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months). Participant will be asked to complete a questionnaire about how they take oral semaglutide tablets during normal scheduled visit with doctor. Participant will also be asked questions about health and their diabetes treatment and lab tests as part of normal doctor's appointment.

Condition or disease

Type 2 Diabetes

Intervention/treatment

Oral Semaglutide

Study Type : OBSERVATIONAL
Estimated Enrollment : 470 participants
Official Title : SEMA-CardioDiab HUNGARY: A Multicentre, Prospective, Non-interventional Study to Evaluate Glycemic Control and Weight Changes in Patients With Type 2 Diabetes Initiating Treatment With Oral Semaglutide by Cardiologists or Diabetologists as Part of Local Clinical Practice in Hungary
Actual Study Start Date : 2024-09-30
Estimated Primary Completion Date : 2026-03-31
Estimated Study Completion Date : 2026-03-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
  • * The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/LAR and the treating physician based on local label before and independently from the decision to include the patient in this study.
  • * Male or female, adults above or equal to 18 years of age at the time of signing informed consent.
  • * Diagnosed with type 2 diabetes mellitus.
  • * Patient on metformin (Met) with or without modern oral antidiabetic (MOAD, that is Dipeptidyl Peptidase-4 Inhibitor \[DPP4i\] or/and Sodium-glucose cotransporter-2 Inhibitor \[SGLT2i\]) with or without insulin therapy.
  • * Available HbA1c value \> 7.0% within 90 days prior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit' (V1) if in line with local clinical practice.
Exclusion Criteria
  • * Previous participation in this study (defined as having given informed consent in this study earlier).
  • * Treatment with any investigational drug within 30 days prior to enrolment into the study.
  • * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
  • * Glucagon like peptide -1 receptor agonist (GLP1-RA) treatment within 90 days prior to the Treatment Initiation visit (V1).
  • * Patients diagnosed with type 1 diabetes mellitus.
  • * Female who is known to be pregnant, undergoing fertility treatment, breastfeeding or intends to become pregnant during the study duration.
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

Location Details

NCT06269120

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

Hungary,

Siklós Hospital, Diabetology

Gliding, Hungary, 7801